Conditions: Schizophrenia
Keywords: Schizophrenia Antipsychotic Agents Mental Disorder Psychotropic Drugs Dopamine Agents Central Nervous System Agents
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 38
Healthy volunteers: no

Brief summary:
The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: MP-214 3mg intervention 2: MP-214 6mg intervention 3: MP-214 9mg
Intervention descriptions: intervention 1: Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks. intervention 2: Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks. intervention 3: Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.

Protocol document: